ArticleUrology2022
Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue.
Article in Urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- [Prevention instead of remediation-screening, lifestyle factors, and prostate care 2.0-transition of urology to healthcare coach : Holistic approach to prostate health].Urologie (Heidelberg, Germany) · 2026Review
- Comparing Gleason Pattern 4 Measurement Approaches on Prostate Biopsy Using Machine Learning: A Proof-of-Principle Study.medRxiv : the preprint server for health sciences · 2026Article
- Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.BJU international · 2025Article
- Surveillance after Focal Therapy - a Comprehensive Review.Prostate cancer and prostatic diseases · 2025Review
- Time to Rethink Gleason Grading.The Journal of urology · 2025Article
- The Absolute Volume of Gleason Pattern 4 on Radical Prostatectomy Is More Strongly Associated With Advanced Stage and Biochemical Recurrence Than Gleason Grade Groups.The Journal of urology · 2025Article
- Confirmatory Biopsy Outcomes in Patients with Grade Group 2 Prostate Cancer: Implications for Early Management.European urology open science · 2025Article
- Size and SUVThe Prostate · 2025Article
- PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?World journal of urology · 2024Article
- Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.BMJ oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate how blood levels of prostate-specific antigen (PSA) relate to prostate volume of benign tissue, Gleason pattern 3 (GP3) and Gleason pattern 4 (GP4) cancer.
methodsThe cohort included 2209 consecutive men undergoing radical prostatectomy at 2 academic institutions with pT2N0, Grade Group 1-4 prostate cancer and an undetectable postoperative PSA. Volume of benign, GP3, and GP4 were estimated. The primary analysis evaluated the association between PSA and volume of each type of tissue using multivariable linear regression. R
resultsEstimated contribution to PSA was 0.04/0.06 ng/mL/cc for benign, 0.08/0.14 ng/mL/cc for GP3, and 0.62/0.80 ng/ml/cc for GP4 for the 2 independent cohorts, respectively. GP4 was associated with 6 to 8-fold more PSA per cc compared to GP3 and 15-fold higher compared to benign tissue. We did not observe a difference between PSA per cc for GP3 vs. benign tissue (P = 0.2). R
conclusionGleason pattern 4 cancer contributes considerably more to PSA and PSA density per unit volume compared to GP3 and benign tissue. Contributions from GP3 and benign are similar. Further research should examine the utility of determining clinical management recommendations by absolute volume of GP4 rather than the ratio of GP3 to GP4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.